A gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy

Cancer

Volumn 83, Issue 5, 1998, Pages 971-976

  Green, Garth A ^a,b   Hanlon, Alexandra L ^a   Al Saleem, Tahseen ^a   Hanks, Gerald E ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b LAC USC MEDICAL CENTER   (United States)

Author keywords

Gleason grade; Prostate carcinoma; Prostate specific antigen; Radiation therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; RADIATION DOSE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032168716     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980901)83:5<971::AID-CNCR24>3.0.CO;2-R     Document Type: Article

References (27)

1. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125-8.
2. Mostofi FK, Sesterhenn IA, Daris CJ. A pathologist's view of prostatic carcinoma. Cancer 1979;44:1490-4.
3. Gleason DF, Mellinger GT, and the Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
4. Murphy GP, Whitmore WF Jr. A report of the workshops on the current status of the histologic grading of prostate cancer. Cancer 1979;44:1490-4.
5. Grignon DJ, Hammond EH. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors: report of the prostate cancer working group. Arch Pathol Lab Med 1995;119:1122-6.
6. Partin AW, Yoo J, Carter B, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage, and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol 1993;150:110-4.
7. Thomas R, Lewis RW, Sarma DP, Coker GB, Rao MK, Roberts JA. Aid to accurate clinical staging-histopathologic grading in prostatic cancer. J Urol 1982;128:726-8.
8. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996;20:286-92.
9. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152:1843-9.
10. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-7.
11. Pilepich MV, Krall JM, Sause WT, Johnson RJ, Russ HH, Hanks GE, et al. Prognostic factors in carcinoma of the prostate: analysis of RTOG 75-06. Int J Radiat Oncol Biol Phys 1987;13:339-49.
12. Bagshaw MA, Cox RS, Ramback JE. Radiation therapy for localized prostate cancer: justification of long-term follow-up. Urol Clin North Am 1990;17:787-802.
13. Zagars GK, Ayala AG, von Eschenbach AC, Pollack A. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 1995;31:237-45.
14. American Joint Committee on Cancer. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Manual for staging of cancer. 4th edition. Philadelphia: J. B. Lippincott, 1992.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:447-57.
16. Mantel N. Estimation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
17. Cox DR. Regression methods and life tables (with discussion). J R Stat Soc 1972;34:187-220.
18. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273-9.
19. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 1995;154:456-9.
20. Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of follow-up. J Urol 1993;149:1478-81.
21. Catalona WJ, Smith DS. 5-Year tumor recurrence rates after anatomical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837-42.
22. Russel KJ, Dunatov C, Hafermann MD, Griffeth JT, Polissar L, Pelton J, et al. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J Urol 1991;146: 1046-52.
23. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993; 20:713-25.
24. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582-93.
25. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prossate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 1997;79:1370-80.
26. McNeal JE, Villers AV, Redwine EA, Freiha FS, Stamey TA. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990;66:1225-33.
27. Bostwick DG. Gleason grading of prostatic needle biopsies: correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 1994;18:796-803.